lodotra
mundipharma gesellschaft m.b.h. - prednizonas - modifikuoto atpalaidavimo tabletės - 5 mg; 2 mg; 1 mg - prednisone
linoladiol-h n
dr. august wolff gmbh & co. kg arzneimittel - estradiolis/prednizolonas - kremas - 0,05 mg/4 mg/g - estradiol, combinations
alpicort
dr. august wolff gmbh & co. kg arzneimittel - prednizolonas/salicilo rūgštis - odos tirpalas - 2 mg/4 mg/ml - prednisolone
alpicort
lex ano, uab - prednizolonas/salicilo rūgštis - odos tirpalas - 2 mg/4 mg/ml - prednisolone
alpicort
limedika, uab - prednizolonas/salicilo rūgštis - odos tirpalas - 2 mg/4 mg/ml - prednisolone
prednisolon-ratiopharm
ratiopharm gmbh - prednizolonas - tabletės - 5 mg - prednisolone
prednisolon-richter
gedeon richter plc - prednizolonas - tabletės - 5 mg - prednisolone
prednisolone polfa
adamed pharma s.a. - prednizolonas - tabletės - 5 mg - prednisolone
prednisolut
nenurodyta - prednizolonas - injekcinis tirpalas - 25 mg/ml - prednisolone
lenalidomide krka d.d. novo mesto (previously lenalidomide krka)
krka, d.d., novo mesto - lenalidomide hydrochloride monohydrate - multiple myeloma; lymphoma, follicular - imunosupresantai - multiple myelomalenalidomide krka d. novo mesto as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide krka d. novo mesto as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) yra nurodytos gydyti suaugusiems pacientams su anksčiau negydytų mieloma, kurie nėra tinkami persodinti. lenalidomide krka d. novo mesto in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. follicular lymphomalenalidomide krka d. novo mesto in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a). multiple myelomalenalidomide krka d. novo mesto as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide krka d. novo mesto as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) yra nurodytos gydyti suaugusiems pacientams su anksčiau negydytų mieloma, kurie nėra tinkami persodinti. lenalidomide krka d. novo mesto in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. follicular lymphomalenalidomide krka d. novo mesto in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a).